paxilline has been researched along with Cancer of Rectum in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Abba, MC; Cuartero, V; Ferretti, VA; Garcia-Fabiani, MB; Lacunza, E; Llontop, A; Palma, S; Perez Verdera, PV; Raffa, CI; Rojas Bilbao, E; Zwenger, A | 1 |
1 other study(ies) available for paxilline and Cancer of Rectum
Article | Year |
---|---|
RHBDD2 overexpression promotes a chemoresistant and invasive phenotype to rectal cancer tumors via modulating UPR and focal adhesion genes.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Adhesion; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Focal Adhesion Kinase 1; Focal Adhesions; Gene Expression Regulation, Neoplastic; HCT116 Cells; Heat-Shock Proteins; Humans; Lymphatic Metastasis; Membrane Proteins; Neoadjuvant Therapy; Paxillin; Protein Binding; Rectal Neoplasms; Signal Transduction; Transcription Factor CHOP; Unfolded Protein Response | 2020 |